Pablo Corral: The Truth About Very Low LDL-Cholesterol
Pablo Corral, Pharmacology Professor at FASTA University, Past President of Argentine Lipid Society, shared a post on LinkedIn about a recent article by Luz Clemencia Zárate-Correa et al., published in Atherosclerosis, adding:
”Our last manuscript is out.
‘Safety of Very Low LDL-Cholesterol:
Ten Common Concerns, Misconceptions, and Evidence-Based Clarifications’
Very low LDL-C levels continue to generate debate, fear, and misinformation in clinical practice.
In this review, we critically examined 10 of the most frequent concerns related to intensive LDL-C lowering:
- Cognitive decline
- Hemorrhagic stroke
- Cancer
- Cataracts
- Hormonal dysfunction
- Diabetes risk
- Muscle symptoms
- Older adults
- Sex differences
- Overall cardiovascular benefit
The key message is clear:
RCTs, meta-analyses, and genetic evidence consistently support the safety profile of very low achieved LDL-C levels in appropriately selected high-risk patients.
- Some adverse effects are real — particularly statin-associated dysglycemia and muscle symptoms — but their absolute risk is generally modest compared with the magnitude of ASCVD risk reduction.
- Therapeutic inertia and misinformation remain major barriers in preventive cardiology. Evidence-based communication matters.
- Lower LDL-C. Earlier. Longer. Safer than many still believe.
Proud to collaborate with outstanding colleagues from Latin America, Europe, and beyond in this international effort.”
Title: Safety of Very Low LDL-Cholesterol: Ten Common Concerns, Misconceptions, and Evidence-Based Clarifications
Authors: Luz Clemencia Zárate-Correa, Ángel García-Peña, Sergio Emanuel Kaiser, Carlos A. Aguilar-Salinas, Máxima Mendez-Castillo, Roopa Mehta, Cynthia M. Valerio, Rodrigo O. Moreira, Leonardo G. Mancillas-Adame, José Antonio Cetina Canto, Juan José Parcero, Ximena Reyes, Meral Kayikcioglu, Alexandros D. Tselepis, Laura Schreier, Pablo Corra

Other featuring Pablo Corral on Hemostasis Today.
-
Nov 13, 2026, 16:17Shailendra Singh: Bombay Hospital Jaipur Inaugurates New Facility with Voluntary Blood Donation Camp
-
Nov 13, 2026, 16:10Minka Zivkovic: UMC Utrecht Announces Research Analyst Vacancy in Thrombosis and Haemostasis
-
Nov 13, 2026, 16:02Rounak Dubey: Elsevier’s Upcoming Handbook Explores Digitalization in Transfusion Medicine
-
Nov 13, 2026, 15:50Maha Othman: CanVECTOR 2026 Highlights Research on Immunothrombosis and Cancer-Associated Thrombosis
-
Nov 13, 2026, 15:48Cedric Hermans: Advances in Gene Therapy for Haemophilia A
-
Nov 13, 2026, 15:45Strengthens Global Collaboration in Thrombosis and Hemostasis for 2027 – ISTH
-
Nov 13, 2026, 15:42David McIntosh: The Global Blood Shortage Crisis and the Urgent Need for National Action
-
Nov 13, 2026, 15:41JTH Highlights Future Directions in Thromboprophylaxis for Hospitalized Children
-
Nov 13, 2026, 15:21Wolfgang Miesbach։ Gene Therapy for Haemophilia B Is Cheaper Than Lifelong Factor IX Prophylaxis in Sweden